Twist Bioscience Co. (NASDAQ:TWST - Get Free Report)'s stock price traded down 5.6% on Friday . The company traded as low as $37.42 and last traded at $36.98. 144,446 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 941,669 shares. The stock had previously closed at $39.18.
Analysts Set New Price Targets
Several brokerages have recently weighed in on TWST. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. TD Cowen restated a "buy" rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Robert W. Baird upped their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target for the company. Finally, Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an "overweight" rating in a research note on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $54.40.
View Our Latest Stock Report on TWST
Twist Bioscience Trading Up 4.4 %
The firm has a market cap of $2.29 billion, a P/E ratio of -11.28 and a beta of 2.15. The business's 50-day moving average is $46.54 and its two-hundred day moving average is $45.47. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience's quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.75) earnings per share. As a group, analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.
Insider Transactions at Twist Bioscience
In related news, CEO Emily M. Leproust sold 1,654 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $44.90, for a total value of $74,264.60. Following the sale, the chief executive officer now directly owns 673,064 shares in the company, valued at $30,220,573.60. This trade represents a 0.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the sale, the senior vice president now directly owns 130,912 shares in the company, valued at $5,355,609.92. The trade was a 0.70 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,845 shares of company stock worth $1,603,945. Insiders own 3.01% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of TWST. Arizona State Retirement System grew its position in Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock valued at $789,000 after buying an additional 219 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after acquiring an additional 267 shares during the period. Hillsdale Investment Management Inc. lifted its position in Twist Bioscience by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock worth $3,625,000 after purchasing an additional 300 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Twist Bioscience by 2.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company's stock valued at $734,000 after purchasing an additional 363 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C boosted its stake in Twist Bioscience by 1.7% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock valued at $1,107,000 after purchasing an additional 403 shares in the last quarter.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.